Infectious Causes of Neoplasia in the Domestic Cat: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Lindsay Dong and Version 1 by Kerry E Rolph.

Malignant transformation due to infectious disease can occur via two broad mechanisms. The agent can act as a direct carcinogen altering the expression of oncogenes; thereby, leading to the production of oncoproteins. These oncoproteins can then interact with cellular proteins, and ultimately lead to mutagenesis by the disruption of cell cycle check-points, inhibition of apoptosis, and enhancement of cell immortalisation. In feline medicine, there have been several viruses which demonstrate direct mutagenesis, these include feline leukaemia virus (FeLV and MMTV) and mouse mammary tumour virus (MMTV). Alternatively, neoplastic transformation can be driven via indirect mechanisms; these include induction of chronic inflammation, which, in turn, results in the production of inflammatory mediators, and the production of reactive oxygen species, which have direct mutagenic effects and promote tumour neovascularisation. Inflammation-induced neoplasms have been associated with  Helicobacter organisms and, potentially, Opisthorchis infections. Furthermore, immune suppression induced by viruses such as feline immunodeficiency virus (FIV), not only predispose to infection with other agents, it is also thought to alter the immune surveillance, and with this, the ability to remove neoplastic cells by the host.

  • retrovirus
  • papillomavirus
  • FeLV
  • FIV
  • Helicobacter
  • lymphoma
  • parasitic

1. Viral Infections Associated with Neoplasia in the Cat

1.1. Feline Leukaemia Virus (FeLV)

Since its discovery in 1964, FeLV has been reported globally [16][1]. It is recognised that progressive infection with FeLV has been shown to increase the risk of lymphoma development by 60 times and is associated with the development of other forms of neoplasia [17,18][2][3]. At its peak, it was estimated that approximately one-third of all cancer related deaths in cats were attributable to FeLV infection [19][4]. However, today the prevalence of FeLV infection is markedly decreased [20][5].

When considering the oncogenic potential of FeLV infection, it is useful to consider the structure, function, and mechanisms of infection. FeLV is an enveloped single-stranded RNA virus with a genome containing three genes: the group specific antigen (gag) gene codes for the structural proteins of the virus; the polymerase (pol) gene codes for reverse transcriptase, protease, and integrase; and the envelope (env) gene codes for the envelope surface glycoprotein gp70 and transmembrane protein p15 [15,26][6][7] (Figure 1). In order to infect the host cell, the envelope glycoprotein spikes first recognise the cell receptor, allowing the viral core to be internalised [16][1]. Two copies of the single-stranded RNA (ssRNA) genome are then released, and using its reverse transcriptase activity, the RNA genome is reverse-transcribed to form DNA [15][6]. This enters the nucleus and is integrated into the host’s cell genome [27][8]. Like all retroviruses, the FeLV genome is flanked by long terminal repeats (LTRs) [16][1]. The integrated virus, known as provirus, then forms the template for production of new virions [15][6].
/media/item_content/202210/6340f5f7a3ae1vetsci-09-00467-g001.png
Figure 1. Schematic representation of FeLV integration within a host cell. The viral genome is depicted at the top of this image. The three genes (gag, pol, and env) within this simple retrovirus are flanked by long terminal repeats (LTRs) comprised of U3, R, and US regions. FeLV serves as an example of retroviral integration into the host DNA, with similar mechanisms employed by both FIV and mouse mammary tumour virus (MMTV).
The term FeLV refers to a group of closely related viral subgroups, namely, exogenous FeLV-A, -B, -C, -D, -E, and -T, and endogenous FeLV (enFeLV), and endogenous retrovirus domestic cat (ERV-DC) [28,29,30,31,32,33,34,35,36,37,38,39,40,41,42][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23]. Endogenous viruses form when proviral elements integrate into host germ cells, becoming a heritable part of the host genome [26][7]. During endogenisation, mutations frequently occur as reverse transcription is error-prone, having no proof-reading function [26][7]. Typically, an endogenised virus is incapable of producing infection, and may provide some protection against exogenous infection [26,43,44][7][24][25]. However, when enFeLVs recombine with exogenous FeLVs, notably in the env region, the biological activity and pathogenicity is altered [16][1].
The outcome of FeLV infection is highly variable, being influenced by the immune status and age of the cat, the pathogenicity of the virus, infection pressure, and virus concentration [20,45][5][26]. Infection most commonly occurs via the oronasal route, after which the virus replicates in local lymphoid tissues [20][5]. In many cats, replication is halted by cell mediated immunity and the virus is completely eliminated from the body [20][5]. In these cases, the virus never spreads systemically, and therefore, they do not react positively to antigen testing. These cats are known as “regressor cats”; they have high levels of neutralising antibodies and build a high level of immunity protecting them against viral challenge for many years [19,20][4][5]. However, if the immune response is not adequate, replicating FeLV spreads within mononuclear cells; this initial viraemic period may cause clinical signs of lethargy, pyrexia, and/or lymphadenopathy [19,20][4][5]. The virus then spreads to target organs which include the spleen, thymus, lymph nodes, and salivary glands. These cats secrete virus in their saliva and are infectious to other cats [19,20][4][5]; generally, this viraemia is transient, lasting only a few weeks before the majority of cats will clear the infection. These cats are termed “transiently viraemic” and will develop effective immunity protecting them against new exposures to virus [19,20][4][5].
In some cases, the infection is not cleared and the bone marrow will become involved, typically within 3 weeks of infection [19,20][4][5]. As a result, affected haematopoietic precursor cells produce infected granulocytes and platelets, which are released into the circulation, at which time there is a high level of viraemia within lymphoid organs and salivary glands also infected [45][26]. A percentage of these cats will go on to clear the viraemia, but do not completely eliminate the virus from the bone marrow; these cats are “latently infected” [19,20][4][5]. Cats which have latent infections can reactivate either spontaneously or when the immune system is suppressed (i.e., in pregnant cats or those receiving high doses of corticosteroids) [46,47][27][28]. Latently infected cats have the viral genome integrated into their cellular chromosomal DNA, which is replicated and passed onto daughter cells. However, the proviral DNA is not translated in proteins, so no infectious viral particles are produced [20][5]. The remaining cats remain “persistently infected”. It is this last group that the majority of FeLV associated mutagenesis has focused upon. Infection with FeLV likely has an indirect effect on lymphomagenesis by leading to immune suppression [16][1]. However, direct mechanisms are also thought to play a significant role in tumour formation.
As a simple retrovirus, the FeLV genome encodes only the genes required for its structure and replication, and therefore, no genes which directly confer malignancy [48][29]. One mechanism by which retroviruses can induce neoplasia is via transduction, whereby the virus acquires a copy of the oncogene during replication; this allows the oncogenic sequence to be transduced along with the virus (removing the gene from its normal transcription unit) [16,48,49][1][29][30]. As oncogenes encode a variety of products, including growth factors, growth factor receptors, and protein kinases, upregulation of these genes favours cell proliferation. This occurs in FeLV-induced multicentric fibrosarcoma; where feline sarcoma viruses (FeFSV) form via transduction of host cellular oncogenes, such as fes, fms, fgr, abi, and kit into FeLV-A [50,51][31][32]. FeFSV is an oncogenic virus, capable of causing polyclonal malignancy with multifocal tumours arising simultaneously after a short incubation period [50][31]. The second mechanism by which FeLV can induce neoplasia is via integration into the cellular genome. Gene expression in retroviruses is directed by the LTRs. The LTR of FeLV has three components, the U3, R, and U5 regions [49][30]. Of these, it is the U3 region which contains transcriptional promoter and enhancer sequences [52][33]. These can act on adjacent viral genes, or on cellular genes near to the site of proviral integration; for example, the U3 region has been demonstrated to transactivate cancer-related signalling pathways through the production of a non-coding 104 base RNA transcript that activates NF-KB [53][34]. If the retrovirus is integrated into the host cell genome near to, for example, a proto-oncogene, such as myc, transcription of that gene can be upregulated [54,55,56,57,58,59,60][35][36][37][38][39][40][41]. This may be mediated by the LTR’s as these contain promoter and enhancer functions; thereby, possessing the potential to regulate the transcription of adjacent cellular genes in the appropriate target cell [52][33]. Tandem repeats of enhancer motifs in the U3 region have been found within FeLV provirus integrated in the genomes of lymphoid neoplasms and leukaemias [16][1]. This suggests that the enhanced expression of the genes adjacent to the integrated proviral genome is associated with oncogenesis [61][42]. Additionally, integration into a tumour suppressor gene can disrupt cellular function, and thereby, the cell can acquire a growth advantage. To date, common integration sites (CISs) for the development of FeLV-associated lymphoma have been identified in six loci, namely: c-myc, flvi-1, flvi-2, fit-1, pim-1, and flit-1 [57,58,62,63,64,65][38][39][43][44][45][46]. Of these, c-myc has been recognised as a proto-oncogene, coding for a nuclear phosphoprotein belonging to a family of transcription factors. In addition, flvi-2, pim-1, and fit-1 have been identified as collaborators. More recently, it was discovered that insertion at the flit-1 locus (which is interrupted in 20% of T-cell thymic lymphoma cases) is associated with the overexpression of activin-A receptor. Activin-A is a multifunctional cytokine, regulating cell growth and differentiation [48,49,66,67][29][30][47][48]. Insertion at the flvi-1 locus is associated with the development of multicentric non-T-cell, non-B-cell lymphoma. Whilst the coding capacity of flvi-1 is unknown, it is thought to encode an oncogene, the activity of which is altered by the adjacent integration of the proviral LTR [61,65][42][46]. It has been suggested that latent or regressive FeLV infection may contribute to lymphomagenesis [16][1]. In these instances, proviral integration could be responsible for the initiation of the neoplastic process. Early studies demonstrated antigen-negative, antibody-positive cats were at a greater risk of lymphoma than cats that had never been exposed to the virus [68,69][49][50]. In addition, some cases have alluded to a potential oncogenic role in regressive infection, with myc having been identified in T-cell lymphoma from an antigen-negative, antibody-positive cat [70,71][51][52]. However, when investigators have looked for provirus to investigate the outcomes in regressive FeLV infection, there are discordant results; some have suggested this is rare [72[53][54][55],73,74], whilst others have suggested as many as 20-60% of lymphomas from antigen-negative cats are provirus positive [75,76,77][56][57][58].

1.2. Feline Immunodeficiency Virus (FIV)

Feline immunodeficiency virus (FIV) is a retrovirus of the lentivirus genus, first described in 1986 [81][59]. Like FeLV, FIV infection leads to the integration of proviral DNA into the host cell DNA; thereby, influencing host cell function. There are six different subtypes recognised, labelled A to F [82][60]. However, infection with one subtype does not protect against infection with a second subtype (superinfection) [82][60]. It has been demonstrated that in superinfected cats, the exchange of gene segments encoding the env protein from different subtypes can occur [82][60]. The prevalence of FIV infection varies widely among different geographic locations, with pockets of high prevalence of up to 47% in some groups of feral cats, compared to that of 2–5% as reported in some studies of healthy, owned cats [83][61]. Generally, seroprevalence is higher in male cats, and adult cats are more likely to be infected than young cats [84][62]. This pattern arises because of the mode of transmission; in natural circumstances, FIV is transmitted primarily via inoculation of the virus present in saliva or blood (i.e., cat fight wounds) [83][61]. Experimentally, the virus can be transmitted in utero, or postpartum via milk or via transmucosal (oral, intrarectal, or intravaginal) inoculation. However, there is no evidence that these routes of infection play an important role in the natural transmission of disease [82,85][60][63]. FIV-infected cats are five to six times more likely to develop lymphoid neoplasia than uninfected cats [18][3]. Concomitant infection with FIV and FeLV increases the likelihood of lymphoma development by nearly 80-fold [18][3]. FIV-associated lymphomas are predominantly high-grade B cell tumours arising at extra-nodal locations [86][64]. Nevertheless, T-cell and non-B, non-T-cell lymphomas have been described in FIV infected cats, as have various other forms of neoplasia, including mast cell tumour, fibrosarcoma, squamous cell carcinoma, and mammary carcinoma [87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80].

1.3. FIV & Gammaherpesviruses

Herpesviruses are a major cause of cancers in immunodeficient humans [114][81]. Some forms of herpesvirus encode several oncogenic proteins, which have been shown to inhibit cellular apoptosis and promote cell survival [86][64]. HIV-associated neoplasms are frequently associated with co-infection with gammaherpesvirus [114,115][81][82]. EBV, a human herpesvirus-4, can be responsible for infectious mononucleosis (glandular fever) [114][81]; although, typically, infection is asymptomatic if individuals are infected during childhood or in early adulthood. However, in immunocompromised humans (post-transplant or HIV/AIDS patients), EBV is linked to the formation of Burkitt’s and Hodgkin lymphomas [114][81].  Kaposi’s sarcoma is a human neoplasm, which occurs in association with HIV and HHV-8 infection [115][82]. Recognition of this association prompted investigations to identify a similar affiliation in feline medicine. In 2014, a feline gammaherpesvirus, Felis catus gammaherpesvirus 1 (FcaGHV1) was first detected [119,120][83][84]. Infection with FcaGHV1 has been reported in Australia, U.S.A., U.K., Europe, Singapore, Japan, and Brazil, with 9.6–23.6% of cats demonstrating viral DNA within their blood [119,120,121,122,123,124,125][83][84][85][86][87][88][89]. Male cats are generally at a higher risk of FcaGHV1 than females [79,121][85][90]. The virus is spread by oropharyngeal shedding, leading to the suggestion that, like FIV, it may be spread by biting [126][91]. 

1.4. Mouse Mammary Tumour Virus (MMTV)

MMTV is an oncogenic retrovirus that induces mammary carcinoma in mice and for which, possible links to human breast cancer have been suggested [128][92]. MMTV is a beta-retrovirus, composed of prominent surface spikes with an eccentric condensed core. The genome codes for both structural and non-structural proteins, and therefore, MMTV is classified as a complex retrovirus [128,131][92][93]. The transcript codes for Gag, Pol, pro-dUTPase (DUT) protein and Env, flanked by LTRs [128][92]. These LTRs are exceptionally long, and encode for two additional genes: sag (a viral accessory protein that functions as a superantigen) and rem (which encodes an RNA export protein) [128][92]. MMTV replicates efficiently in the mammary alveolar epithelial cells, with increased expression observed during lactation due to the release of steroid hormones [128][92]. In mice, lactogenic transmission results in the virus infecting the dendritic cells and B lymphocytes of the Peyer’s patches. The sag antigen is then presented to CD4+ T-lymphocytes. This protein triggers viral replication and amplification of T-lymphocytes, which act as a carrier to transfer the virus from the gut to the mammary tissue. MMTV infection does not immediately trigger neoplastic transformation, even once proviral DNA is inserted in the cell DNA [128][92]. The insertion results in proto-oncogene deregulation (much like infection with FeLV). To date, rearrangements in several cellular gene families (wnt, fgf, notch4/int3, rspo and the gene encoding the p48 component of eukaryotic translation initiation factor-3 (elF-3p48)) have been demonstrated with MMTV infection [128,129][92][94]. It is hypothesised that these insertions are responsible for neoplastic transformation. However, indirect mechanisms for MMTV tumorigenesis have also been implicated [132][95]. It has been suggested that MMTV may activate an immunoreceptor tyrosine-based mechanism that suppresses apoptosis [132][95]. Alternatively, it has been hypothesised that MMTV infection could lead to the activation of other infections, such as EBV or HPV, which have also been implicated in the development of mammary neoplasia [132][95].

1.5. Papillomaviruses

One of the strongest associations between an infectious agent and neoplasia in humans is the role of papillomaviruses in cervical carcinoma [2][96]. There are currently six different feline papillomaviruses recognised; Felis catus papillomavirus types 1-6 (FcaPV 1-6) [141][97]. Cats are also dead-end hosts for the delta-papillomavirus Bos taurus papillomavirus-14 (BPV-14) [141][97]. The majority of cats are infected with FcaPV’s, but disease associated with infection is rare, suggesting that, in most circumstances, host defences inhibit viral replication [142][98]. Occasionally, papillomaviruses can induce a rapid (self-limited) increase in cell growth, resulting in a hyperplastic papilloma (wart) or a more modest increase in cell growth, leading to the development of a raised plaque [139][99]. The increased replication within cells can lead to neoplastic transformation [139][99]. There are various cutaneous lesions that have been associated with papillomavirus infection in cats. These include, cutaneous papilloma’s (warts), which are rare in the cat; viral plaques and Bowenoid in situ carcinoma (BISC); feline cutaneous squamous cell carcinoma (SCC); basal cell carcinoma (BCC), feline sarcoid, and Merkle cell carcinoma [149,150,151][100][101][102]. In addition, oral papilloma’s and oral squamous cell carcinoma (OSCC) have been linked to feline papillomavirus infection [141][97].

Feline viral plaques and BISC are thought to represent two extremes of the same disease process [142][98]. These lesions typically develop in middle to older aged cats [140][103]. They can be found anywhere on the body, but are most common around the head and neck. Viral plaques are small (less than 8mm) slightly raised, hairless lesions, whereas BISCs are larger, more markedly raised, ulcerated, and crusted lesions [141][97]. The lesions are considered pre-cancerous, but can progress to invasive squamous cell carcinoma in some cases [141][97]. Studies have demonstrated that both viral plaques and BISCs are frequently associated with FcaPV-2 infection [146,147,148,152,153,154,155,156][104][105][106][107][108][109][110][111]. The most common cause of viral plaques/BISC is FcaPV-2, which was identified in 48% of BISCs using immunohistochemistry [157][112]. 

Cutaneous SCC in cats are most notably associated with UV-light exposure. However, there is evidence that FcaPVs may also play a role. Initially, it was noted that FcaPV-2 was identified more frequently in SCC than in non-SCC skin [158,161][113][114]. However, FcaPV-2 E6 and E7 RNA has also been identified in a proportion of SCCs, but not normal skin; more recently, the E6 and E7 proteins have been shown to influence neoplastic transformation [144,162,163][115][116][117]. FcaPVs have been detected in 76% of SCCs occurring in UV-protected (i.e., haired) areas, and 42% of SCCs from UV-exposed skin [164][118]. Furthermore, p16 has been identified in 84% of UV-protected SCC and 40% of UV-exposed SCC [146,164][104][118].

BCCs are not common in cats [139][99]. However, it has been noted that they are often associated with adjacent BISC lesions, and therefore, it was suggested that FcaPVs may be linked to their occurrence. A cat with multiple BCCs that contained FcaPV-3 DNA has been reported, as has a case with a novel PV type [169,170][119][120]. These cases demonstrated classic papillomavirus-induced changes within the neoplastic cells. However, as so few feline papillomavirus-associated BCCs have been reported, the role of these infections in tumour formation remains undetermined. Feline sarcoids are caused by proliferating mesenchymal cells. These lesions are thought to be caused by infection with BPV-14, which appears to be able to lead to cross-species infection. Only cats with contact to cattle are reported to be affected. There is no viral replication within the lesions, and no L1 immunostaining [171][121]. However, BPV-14 is consistently detected within feline sarcoids [172[122][123],173], but not in unaffected samples [174][124]. In situ hybridisation has demonstrated papillomavirus DNA within the neoplastic mesenchymal cells [171][121]. Together these support a causal role of BPV-14 in feline sarcoid formation. Aside from the cutaneous manifestations, FcaPVs have been implicated in the development of oral lesions, oral papillomas, and OSCCs. Oral papillomas are rare in the cat; they tend to be restricted to the ventral surface of the tongue and are usually incidental findings [141][97]. In the few cases in which investigations have been performed, the lesions have demonstrated prominent papilloma-induced changes, and have stained positive for L1 or p16 [175,176][125][126]. Virus typing has only been performed in two cases, with FcaPV-1 being isolated in both of these [176][126]. OSCCs are aggressive, invasive neoplasms which are associated with short survival time, particularly when measures to achieve local control of the tumour are not pursued [141][97]. As papillomaviruses have been linked to human OSCCs and feline cutaneous SCCs, it has been hypothesised that FcaPVs may play a role in the formation of feline OSCCs. In two studies, assessing a total of 52 OSCCs, papillomavirus DNA was amplified from three tumours; there was no amplification from 20 non-neoplastic oral samples [177,178][127][128]. Of the three sequences amplified, two were found to be HPV, whereas the remaining one could not be sequenced. This could reflect infection or, equally, contamination. Overall, studies have produced highly variable results; both a study in New Zealand assessing a series of 30 OSCCs, and a study from Japan assessing seven OSCCs, failed to demonstrate the presence of FcaPV DNA [168,179][129][130]. However, some studies have detected FcaPVs, including another study from New Zealand, in which 36 OSCCs and 16 gingivitis cases were assessed; FcaPV-1 was identified in one case of OSCC and one of gingivitis [168,180][129][131].

1.6. Hepadnavirus

In feline medicine, the majority of the research to date has focused on the roles of the retroviruses and papillomaviruses in neoplastic transformation. However, in humans, viral hepatopathies have long been established as a cause of hepatitis and hepatocellular carcinoma; approximately 35% of pathogen related cancers are attributed to hepatic neoplasia of viral origin [183][132].  Recently, a novel hepadnavirus, similar to HBV, has been identified in domestic cats (domestic cat hepadnavirus, DCH) [184][133]. Studies have demonstrated that 6.5–10.8% of pet cats are positive for DCH [184,185][133][134]. A retrospective study using PCR and in situ hybridisation techniques demonstrated that 43% of chronic hepatitis cases, and 28% of HCCs, were positive for DCH [186][135]. In comparison, no cats with cholangitis, biliary carcinoma, or normal liver, tested positive for DCH. Additionally, the histological features of the DCH-positive cases demonstrated histopathological features similar to those reported in humans with HBV [127][136].

2. Bacterial Causes of Neoplasia

In cats, several enterohepatic Helicobacter species have been recognised. A study in 2001 demonstrated Helicobacter species in 17 of 45 cats [197][137]. Of these, nine were demonstrated as having H. heilmannii, four were positive for H. felis, three were positive for both H. felis and H. heilmannii, and seven for unclassified Helicobacter species [197][137]. There is a single report of Helicobacter organisms in cats with gastric lymphoma [196][138]. Of the cases with gastric lymphoma, 17 were identified with lymphoblastic lymphoma. In that study, histopathological samples from 47 cats with gastro-intestinal disease were assessed; 14 demonstrated gastritis, 31 lymphoma, and 2 were normal. It was found that ‘sick’ cats were more likely to host Helicobacter organisms. Furthermore, 13/17 cases of lymphoblastic lymphoma were positive for H. heilmannii by fluorescent in situ hybridisation [196][138].

3. Parasitic Infections

One of the first reports of neoplasia occurring in association with infection was the observation that bladder cancers were more prevalent in men with schistosomiasis [8][139]. Since this time, it has been demonstrated in humans that the helminth-associated diseases, schistosomiasis, opisthorchiasis, and clonorchiasis, are highly carcinogenic [200][140]. Furthermore, it has been shown that the protozoal organism, Trypanosoma cruzi, has a dual role of being both carcinogenic and anti-carcinogenic [200][140]. The malaria parasite, Plasmodium falciparum, is strongly associated with Burkitt lymphoma in endemic areas, but only when co-infection with EBV is present [200][140].

One early report documented four cases of cholangiocarcinoma in cats parasitised by Platynosomum fastosum (P. fastosum) [201][141]. However, despite numerous reports of biliary tract infection by this trematode, there were no further reports of neoplasia until 2012, when post mortems of 3 of 11 cats infected with P. fastosum were reported to have cholangiocarcinoma [202][142]. In addition, there is a single case report of a cat with biliary cystadenoma associated with Opisthorchis viverrini infection [203][143], and, to date, there are no reports of Opisthorchis felineus leading to biliary neoplasia in the cat, despite reports in many other species [204,205,206][144][145][146].

4. Conclusion

Infectious causes of neoplasia is a rapidly evolving area of interest in human medicine and there are many examples in veterinary medicine. Current research in feline medicine has focused predominantly on the retroviruses and FcaPVs, where a direct oncogenic role has been demonstrated in FeLV, FIV (occasionally), and some FcaPVs. The role of concurrent infections, such as FIV and FcaGHV-1, is currently being explored. Additionally, there is emerging evidence that other organisms, such as MMTV, hepadnavirus, Helicobacter infections, as well as other bacterial or parasitic infections, may be involved in neoplastic processes, either by direct or indirect mechanisms. There is clear evidence that FeLV has a direct effect on the cell, inducing neoplastic transformation. However, the potential protective role enFeLV and the mechanisms by which LTRs influence mutagenesis is not clearly understood. A better understanding of these processes could lead to advances in ourthe ability to protect from tumorigenesis. Despite these gaps in ourthe knowledge, FeLV is the best understood mutagenic organism in the feline species. The precise mechanisms by which FIV and FcaGHV-1 initiate neoplastic transformation, and the role of co-infection with these viruses, remains unknown. Recently, there have been some advances in ourthe understanding of MMTV in humans, but as yet, the role of this infection in feline neoplasms is unknown. Outside of the retroviral infections, FcaPVs have been most widely investigated, and both direct and indirect mechanisms of tumorigenesis have been identified. However, the role of FcaPVs in certain forms of neoplasia is a rapidly evolving area of interest. The recent discovery of hepadnavirus and a potential role of DCH in feline hepatic diseases is currently in its infancy. However, if infection mirrors disease in other species, there could be the potential to protect against some forms of hepatic neoplasia. Documented evidence of bacterial or parasitic causes of neoplasia in the cat are sparse, with the only a few case reports detailing neoplasms in cats with bacterial or parasitic infections. Despite this, there is evidence of tumorigenesis occurring secondary to these organisms in other species. Considering these associations, it is important that veterinarians consider a potential role of infections in the development of neoplasms. Developing a better understanding of these processes, including the specific mechanisms by which different organisms influence the neoplastic process, could help in protecting against/treating various forms of neoplasia in the future.

References

  1. Beatty, J. Viral causes of feline lymphoma: Retroviruses and beyond. Vet. J. 2014, 201, 174–180.
  2. Rezanka, L.J.; Rojko, J.L.; Neil, J.C. Feline leukemia virus: Pathogenesis of neoplastic disease. Cancer Investig. 1992, 10, 371–389.
  3. Shelton, G.H.; Grant, C.K.; Cotter, S.M.; Gardner, M.B.; Hardy, W.D., Jr.; DiGiacomo, R.F. Feline immunodeficiency virus and feline leukemia virus infections and their relationships to lymphoid malignancies in cats: A retrospective study (1968–1988). J. Acquir. Immunedeficiency Syndr. 1990, 3, 623–630.
  4. Hartmann, K. Clinical aspects of feline immunodeficiency and feline leukemia virus infection. Vet. Immunol. Immunopathol. 2011, 143, 190–201.
  5. Lutz, H.; Addie, D.; Belák, S.; Boucraut-Baralon, C.; Egberink, H.; Frymus, T.; Gruffydd-Jones, T.; Hartmann, K.; Hosie, M.J.; Lloret, A.; et al. Feline leukaemia. ABCD guidelines on prevention and management. J. Feline Med. Surg. 2009, 11, 565–574.
  6. Willett, B.J.; Hosie, M.J. Feline Leukaemia virus: Half a century since its discovery. Vet. J. 2013, 195, 16–23.
  7. Chiu, E.S.; Hoover, E.A.; VandeWoude, S. A retrospective examination of Feline Leukemia subgroup characterization: Viral interference assays to deep sequencing. Viruses 2018, 10, 10010029.
  8. Arico, D.; Drago, V.; Foster, P.S.; Heilman, K.M.; Williamson, J.; Ferri, R. Effects of NREM sleep instability on cognitive processing. Sleep Med. 2010, 11, 791–798.
  9. Jarrett, O.; Hardy, W.D., Jr.; Golder, M.C.; Hay, D. The frequency of occurrence of feline leukaemia virus subgroups in cats. Int. J. Cancer 1978, 21, 334–337.
  10. Jarrett, O.; Russel, P.H. Differential growth and transmission in cats of feline leukaemia viruses of subgroups A and B. Int. J. Cancer 1978, 21, 466–472.
  11. Sarma, P.S.; Log, T. Subgroup classification of feline leukemia and sarcoma viruses by viral interference and neutralization tests. Virology 1973, 54, 160–169.
  12. Sarma, P.S.; Log, T. Viral interference in feline leukemia-sarcoma complex. Virology 1971, 44, 352–358.
  13. Stewart, H.; Jarrett, O.; Hosie, M.J.; Willett, B.J. Are endogenous feline leukemia viruses really endogenous? Vet. Immunol. Immunopathol. 2011, 143, 325–331.
  14. Stewart, M.A.; Warnock, M.; Wheeler, A.; Wilkie, N.; Mullins, J.I.; Onions, D.E.; Neil, J.C. Nucleotide sequences of a feline leukemia virus subgroup A envelope gene and long terminal repeat and evidence of the recombinational origin of subgroup B viruses. J. Virol. 1986, 58, 825–834.
  15. Roy-Burman, P. Endogenous env elements: Partners in generation of pathogenic feline leukemia viruses. Virus Genes 1996, 1996, 147–161.
  16. Hoover, E.A.; Kociba, G.J.; Hardy, W.D., Jr.; Yohn, D.S. Erythroid hypoplasia in cats inoculated with feline leukemia virus. J. Natl. Cancer Inst. 1974, 53, 1271–1276.
  17. Mackey, L.; Jarrett, W.; Jarrett, O.; Laird, H. Anemia associated with feline leukemia virus infection in cats. J. Natl. Cancer Inst. 1975, 54, 209–217.
  18. Tury, S.; Giovannini, D.; Ivanova, S.; Touhami, J.; Courgnaud, V.; Battini, J.L. Identification of Copper Transporter 1 as a Receptor for Feline Endogenous Retrovirus ERV-DC14. J. Virol. 2022, 96, e0022922.
  19. Anai, Y.; Ochi, H.; Watanabe, S.; Nakagawa, S.; Kawamura, M.; Gojobori, T.; Nishigaki, K. Infectious endogenous retroviruses in cats and emergence of recombinant viruses. J. Virol. 2012, 86, 8634–8644.
  20. Miyake, A.; Kawasaki, J.; Ngo, H.; Makundi, I.; Muto, Y.; Khan, A.H.; Smith, D.J.; Nishigaki, K. Reduced Folate Carrier: An Entry Receptor for a Novel Feline Leukemia Virus Variant. J. Virol. 2019, 93, e00269-19.
  21. Miyake, A.; Watanabe, S.; Hiratsuka, T.; Ito, J.; Ngo, M.H.; Makundi, I.; Kawasaki, J.; Endo, Y.; Tsujimoto, H.; Nishigaki, K. Novel Feline Leukemia Virus Interference Group Based on the env Gene. J. Virol. 2016, 90, 4832–4837.
  22. Donahue, P.R.; Quackenbush, S.L.; Gallo, M.V.; deNoronha, C.M.C.; Overbaught, J.; Hoover, E.A.; Mullins, J.I. Viral genetic determinants of T-cell killing and immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS. J. Virol. 1991, 65, 4461–4469.
  23. Mullins, J.I.; Hoover, E.A.; Overbaugh, J.; Quackenbush, S.L.; Donahue, P.R.; Poss, M.L. FeLV-FAIDS induced immunodeficiency syndrome in cats. Vet. Immunol. Immunopathol. 1989, 21, 25–37.
  24. Chiu, E.S.; VandeWoude, S. Presence of Endogenous Viral Elements Negatively Correlates with Feline Leukemia Virus Susceptibility in Puma and Domestic Cat Cells. J. Virol. 2020, 94, e01274-20.
  25. Chiu, E.S.; McDonald, C.A.; VandeWoude, S. Endogenous Feline Leukemia Virus (FeLV) siRNA transcription may interfere with exogenous FeLV infection. J. Virol. 2021, 95, e00070-00021.
  26. Hartmann, K. Feline leukemia virus infection. In Infectious Diseases of the Dog and Cat, 4th ed.; Greene, C.E., Ed.; Elsevier Saunders: St Louis, MO, USA, 2012; pp. 108–136.
  27. Pacitti, A.M.; Jarrett, O.; Hay, D. Transmission of feline leukaemia virus in the milk of a non-viraemic cat. Vet. Rec. 1986, 118, 381–384.
  28. Rojko, J.L.; Hoover, E.A.; Quackenbush, S.L.; Olsen, R.G. Reactivation of latent feline leukaemia virus infection. Nature 1982, 298, 385–388.
  29. Fujino, Y.; Ohno, K.; Tsujimoto, H. Molecular pathogensis of feline leukemia virus-induced malignancies: Insertional mutagenesis. Vet. Immunol. Immunopathol. 2008, 123, 138–143.
  30. Fujino, Y.; Liao, C.-P.; Zhao, Y.-S.; Pan, J.; Mathes, L.E.; Hayes, K.A.; Ohno, K.; Tsujimoto, H.; Roy-Burman, P. Identification of a novel common proviral integration site, flit-1, in feline leukemia virus induced thymic lymphoma. Virology 2009, 386, 16–22.
  31. Hardy, W.D., Jr. The Feline Sarcoma Viruses. J. Am. Anim. Hosp. Assoc. 1981, 17, 981–997.
  32. Bonham, L.; Lobellerich, P.A.; Henderson, L.A.; Levy, L.S. Transforming potential of a myc-containing variant of feline leukemia-virus in vitro in early passage feline cells. J. Virol. 1987, 61, 3072–3081.
  33. Rohn, J.L.; Linenberger, M.L.; Hoover, E.A.; Overbaugh, J. Evolution of Feline Leukemia Virus variant genomes with insertions, deletions, and defective envelope genes in infected cats with tumours. J. Virol. 1994, 68, 2458–2467.
  34. Forman, L.W.; Pal-Ghosh, R.; Spanjaard, R.A.; Faller, D.V.; Ghosh, S.K. Identification of LTR-specific small non-coding RNA in FeLV infected cells. FEBS Lett. 2009, 583, 1386–1390.
  35. Forrest, D.; Onions, D.E.; Lees, G.; Neil, J.C. Altered structure and expression of c-myc in feline T-cell tumours. Virology 1987, 158, 194–205.
  36. Miura, T.; Shibuya, M.; Tsujimoto, H.; Fukasawa, M.; Hayami, M. Molecular cloning of a feline leukemia provirus adjacent to the c-myc gene in a feline T-cell leukemia cell line and the unique structure of its long terminal repeat. Virology 1989, 169, 458–461.
  37. Miura, T.; Tsujimoto, H.; Fukasawa, M.; Kodama, T.; Shibuya, M.; Hasegawa, A.; Hayami, M. Structural abnormality and over-expression of the myc gene in feline leukemias. Int. J. Cancer 1987, 40, 564–569.
  38. Levy, L.S.; Lobelle-Rich, P.A.; Overbaugh, J.; Abkowitz, J.L.; Fulton, R.; Roy-Burman, P. Coincident involvement of flvi-2, c-myc, and novel env genes in natural and experimental lymphosarcomas induced by feline leukemia virus. Virology 1993, 196, 892–895.
  39. Tsatanis, C.; Fulton, R.; Nishigaki, K.; Tsujimoto, H.; Levy, L.S.; Terry, A.; Speandidos, D.; Onions, D.E.; Neil, J.C. Genetic determinants of feline leukemia virsu-induced lymphoid tumors: Patterns of proviral insertion and gene rearrangement. J. Virol. 1994, 68, 8296–8303.
  40. Neil, J.C.; Hughes, D.; McFarlane, R.; Wilkie, N.M.; Onions, D.E.; Lees, G.; Jarrett, O. Transduction and rearrangement of the myc gene by feline leukaemia virus innnaturally occurring T-cell leukaemias. Nature 1984, 308, 814–820.
  41. Levy, L.S.; Gardner, M.B.; Casey, J.W. Isolation of a feline leukaemia provirus containing the oncogene myc from a feline lymphosarcoma. Nature 1984, 308, 853–856.
  42. Bolin, L.L.; Levy, L.S. Viral determinants of FeLV infection and pathogenesis: Lessons learned from analysis of an natural cohort. Viruses 2011, 3, 1681–1698.
  43. Levy, L.S.; Lobelle-Rich, P.A.; Overbaugh, J. flvi-2, a target of retroviral insertional mutagenesis in feline thymic lymphosarcoma, encodes bmi-1. Oncogene 1993, 8, 1833–1838.
  44. Levy, L.S.; Lobelle-Rich, P.A. Insertional mutagenesis of flvi-2 in tumors induced by infection with LC-FeLV, a myc-containing strain of feline leukemia virus. J. Virol. 1992, 66, 2885–2892.
  45. Tsujimoto, H.; Fulton, R.; Nishigaki, K.; Matsumoto, Y.; Hasegawa, A.; Tsujimoto, A.; Cevario, S.; O’Brien, S.J.; Terry, A.; Onions, D.E.; et al. A common proviral integration region, fit-1, in T-cell tumors induced by myc-containing feline leukemia viruses. Virology 1993, 196, 845–848.
  46. Levesque, K.S.; Bonham, L.; Levy, L.S. flvi-1, a common integration domain of feline leukemia virus in naturally occurring lymphomas of a particular type. J. Virol. 1990, 64, 3455–3462.
  47. Attisano, L.; Carcamo, J.; Ventura, F.; Weis, F.M.; Massague, J.; Wrana, J.L. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993, 75, 671–680.
  48. ten Dijke, P.; Ichijo, H.; Franzen, P.; Schulz, P.; Saras, J.; Toyoshima, H.; Heldin, C.H.; Miyazono, K. Activin receptor-like kinases: A novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 1993, 8, 2879–2887.
  49. Francis, D.P.; Essex, M.; Cotter, S.M.; Gutensohn, N.; Jakowski, R.; Hardy, W.D., Jr. Epidemiological association between virus-negative feline leukemia and the horizontally trasmitted feline-leukemia virus. Cancer Res. 1981, 39, 3866–3870.
  50. Hardy, W.D., Jr.; McClelland, A.J.; Zuckerman, E.E.; Snyder, H.W., Jr.; MacEwen, E.G.; Francis, D.; Essex, M. Development of virus non-producer lymphosarcomas in pet cats exposed to FeLV. Nature 1980, 288, 90–92.
  51. Rojko, J.L.; Kociba, G.J.; Abkowitz, J.L.; Hamilton, K.L.; Hardy, W.D., Jr.; Ihle, J.N.; O’Brien, S.J. Feline lymphomas-immunological and cytochemical characterization. Cancer Res. 1989, 49, 345–351.
  52. Fulton, R.; Forrest, D.; McFarlane, R.; Onions, D.E.; Neil, J.C. Retroviral transduction of T-cell antigen receptor b-chain and myc genes. Nature 1987, 326, 190–194.
  53. Beatty, J.A.; Tasker, S.; Jarrett, O.; Lam, A.; Gibson, S.; Noe-Nordberg, A.; Phillips, A.; Fawcett, A.; Barrs, V.R. Marker of feline leukaemia virus infection or exposure in cats from a region of low seroprevalence. J. Feline Med. Surg. 2011, 13, 927–933.
  54. Stützer, B.; Simon, K.; Lutz, H.; Majzoub, M.; Hermanns, W.; Hirschberger, J.; Sauter-Louis, C.; Hartmann, K. Incidence of persistent viraemia and latent feline leukaemia virus infection in cats with lymphoma. J. Feline Med. Surg. 2011, 13, 81–87.
  55. Herring, E.S.; Troy, G.C.; Toth, T.E.; Forrester, S.D.; Weigt, L.A.; Herring, I.P. Detection of feline leukaemia vius in blood and bone marrow of cats with carying suspicion of latent infection. J. Feline Med. Surg. 2001, 3, 133–141.
  56. Gabor, L.J.; Jackson, M.L.; Trask, B.; Malik, R.; Canfield, P.J. Feline leukaemia virus status of Australian cats with lymphosarcoma. Aust. Vet. J. 2001, 79, 476–481.
  57. Jackson, M.L.; Haines, D.M.; Meric, S.M.; Misra, V. Feline leukemia virus detection by immunohistochemistry and polymerase chain-reaction in formalin-fixed, paraffin-embedded tumor tissue from cats with lymphosarcoma. Can. J. Vet. Res. Rev. Can. Rech. Vet. 1993, 57, 269–276.
  58. Weiss, A.T.A.; Klopfleisch, R.; Gruber, A.D. Prevalence of feline leukaemia provirus DNA in feline lymphomas. J. Feline Med. Surg. 2010, 12, 929–935.
  59. Pedersen, N.C.; Ho, E.W.; Brown, M.L.; Yamamoto, J.K. Isolation of a T-lymphotrophic virus from domestic cats with an immunodeficiency like syndrome. Science 1987, 235, 790–793.
  60. Sellon, R.K.; Hartmann, K. Feline immunodeficiency virus infection. In Infectious Diseases of the Dog and Cat, 4th ed.; Greene, C.E., Ed.; Elsevier Saunders: St Louis, MO, USA, 2012; pp. 136–149.
  61. Hosie, M.J.; Addie, D.; Belak, S.; Boucraut-Baralon, C.; Egberink, H.; Frymus, T.; Gruffydd-Jones, T.; Hartmann, K.; Lloret, A.; Lutz, H.; et al. Feline Immunodeficiency. ABCD guidelines on prevention and management. J. Feline Med. Surg. 2009, 11, 575–584.
  62. Liem, B.P.; Dhand, N.K.; Pepper, A.E.; Barrs, V.R.; Beatty, J. Clinical features and survival in cats naturally infected with feline immunodeficiency virus. J. Vet. Intern. Med. 2013, 27, 798–805.
  63. Addie, D.; Belák, S.; Boucraut-Baralon, C.; Egberink, H.; Frymus, T.; Gruffydd-Jones, T.; Hartmann, K.; Hosie, M.J.; Lloret, A.; Lutz, H.; et al. Feline infectious peritonitis. ABCD guidelines on prevention and management. J. Feline Med. Surg. 2009, 11, 594–604.
  64. Magden, E.; Quackenbush, S.L.; VandeWoude, S. FIV associated neoplasms-A mini-review. Vet. Immunol. Immunopathol. 2011, 143, 227–234.
  65. Callanan, J.J.; Jones, B.A.; Irvine, J.; Willett, B.J.; McCandlish, I.A.P.; Jarrett, O. Histological classification and immunophenotype of lymphosarcoma in cats with naturally and experimentally acquired feline immunodeficiency virus infections. Vet. Pathol. 1996, 33, 264–272.
  66. Terry, A.; Callanan, J.J.; Fulton, R.; Jarrett, O.; Neil, J.C. Molecular analysis of tumours from feline immunodeficiency virus (FIV)-infected cats: An indirect role for FIV? Int. J. Cancer 1995, 61, 227–232.
  67. Gabor, L.J.; Love, D.N.; Malik, R.; Canfield, P.J. Feline Immunodeficiency virus status of Australian Cats with lymphosarcoma. Aust. Vet. J. 2001, 79, 540–545.
  68. Rosenburg, M.P.; Hohenhaus, A.E.; Matus, R.E. Monoclonal gammopathy and lymphoma in a cat infected with feline immunodeficiency virus. J. Am. Anim. Hosp. Assoc. 1991, 27, 335–337.
  69. Endo, Y.; Cho, K.W.; Nishigaki, K.; Monoi, Y.; Nischimura, Y.; Mizuno, T.; Goto, Y.; Watari, T.; Tsujimoto, H.; Hasegawa, A. Molecular characteristics of malignant lymphomas in cats naturally infected with feline immunodeficiency virus. Vet. Immunol. Immunopathol. 1997, 123, 153–167.
  70. Wang, J.; Kyaw-Tanner, M.; Lee, C.; Robinson, W.F. Characterization of lymphosarcomas in Australian cats using polymerase chain reaction and immunohistochemical examination. Aust. Vet. J. 2001, 79, 41–46.
  71. Ishida, T.; Washizu, T.; Toriyabe, K.; Motoyoshi, S.; Tomodo, I.; Pedersen, N.C. FIV infection in cats of Japan. J. Am. Vet. Med. Assoc. 1989, 194, 221–225.
  72. Hutson, C.; Rideout, B.A.; Pedersen, N.C. Neoplasia associated with Feline Immunodeficiency virus infection in cats of southern California. J. Am. Vet. Med. Assoc. 1991, 199, 1357–1362.
  73. Yamomoto, J.K.; Hansen, H.; Ho, E.W.; Morishita, T.Y.; Okuda, T.Y.; Sawa, T.R.; Nakamura, R.M.; Pedersen, N.C. Epidemiological and clincial aspects of feline immunodeficiency virus in cats from the continental United States and Canada and possible mode of transmission. J. Am. Vet. Med. Assoc. 1989, 194, 213–220.
  74. Alexander, R.; Robinson, W.F.; Mill, J.N.; Sherry, C.R.; Sherard, E.; Paterson, A.J.; Shaw, S.E.; Clark, W.T.; Hollingsworth, T. Isolation of feline immunodeficiency cirus from three cats with lymphoma. Aust. Vet. Pract. 1989, 19, 93–97.
  75. Sabine, M.; Michelsen, J.; Thomas, F.; Zheng, M. Feline AIDS. Aust. Vet. Pract. 1988, 18, 105–107.
  76. Hopper, C.D.; Sparkes, A.H.; Gruffydd-Jones, T.; Crispin, S.M.; Muir, P.; Harbour, D.A.; Stokes, C.R. Clinical and laboratory findings in cats infected with Feline Immunodeficiency Virus. Vet. Rec. 1989, 125, 321–346.
  77. Beatty, J.A.; Lawrence, C.E.; Callanan, J.J.; Grant, C.K.; Gault, E.A.; Neil, J.C.; Jarrett, O. Feline Immunodeficiency virus (FIV)-associated lymphoma: A potential role for immune dysfunction in tumourigenesis. Vet. Immunol. Immunopathol. 1998, 65, 309–322.
  78. Callanan, J.J.; McCandlish, I.A.P.; O’Neil, B.; Lawrence, C.E.; Rigby, M.; Pacitti, A.M.; Jarrett, O. Lymphosarcoma in experimentally induced feline immunodeficiency virus infection. Vet. Rec. 1992, 130, 293–295.
  79. Poli, A.; Abramo, F.; Cavicchio, P.; Bandecchi, P.; Ghelardi, E.; Pistello, M. Malignant lymphoma associated with experimentally induced feline immunodeficiency virus infection. J. Comp. Pathol. 1994, 110, 319–328.
  80. Shelton, G.H.; Waltier, R.M.; Connor, S.C.; Grant, C.K. Prevalence of feline immunodeficiency virus and deline leukaemia virus infections in pet cats. J. Am. Anim. Hosp. Assoc. 1989, 25, 7–12.
  81. Rahman, R.; Gopinath, D.; Buajeeb, W.; Poomsawat, S.; Johnson, N.W. Potential role of Epstein-Barr virus in oral potentially malignant disorders and oral squamous cell carcinoma: A scoping review. Viruses 2022, 14, 801.
  82. Cesarman, E. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett. 2011, 305, 163–174.
  83. Beatty, J.A.; Troyer, R.M.; Carver, S.; Barrs, V.R.; Espinasse, F.; Conradi, O.; Stutzman-Rodriguez, K.; Chan, C.C.; Tasker, S.; Lappin, M.R.; et al. Felis catus gammaherpesvirus 1; a widely endemic potential pathogen of domestic cats. Virology 2014, 460, 100–107.
  84. Troyer, R.M.; Beatty, J.A.; Stutzman-Rodriguez, K.R.; Carver, S.; Lozano, C.C.; Lee, J.S.; Lappin, M.R.; Riley, S.P.D.; Serieys, L.E.K.; Logan, K.A.; et al. Novel gammaherpesviruses in north American domestic cats, bobcats, and pumas: Identification, prevalence, and risk factors. J. Virol. 2014, 88, 3914–3924.
  85. Ertl, R.; Korb, M.; Langbein-Detsch, I.; Klein, D. Prevalence and risk factors of gammaherpesvirus infection in domestic cats in Central Europe. J. Virol. 2015, 12, 146.
  86. Kurissio, J.K.; Rodrigues, M.V.; Taniwaki, S.A.; de Souza Zanutto, M.; Filoni, C.; Galdino, M.V.; Araújo, A.P., Jr. Felis catus gammaherpesvirus 1 (FcaGHV1) and coinfections with feline viral pathogens in domestic cats in Brazil. Cienc. Rural. 2018, 48, e20170480.
  87. Makundi, I.; Koshida, Y.; Endo, Y.; Nishigaki, K. Identification of Felis catus Gammaherpesvirus 1 in Tsushima Leopard Cats (Prionailurus bengalensis euptilurus) on Tsushima Island, Japan. Viruses 2018, 1, 378.
  88. McLuckie, A.; Tasker, S.; Dhand, N.K.; Spencer, S.; Beatty, J.A. High prevalence of Felis catus gammaherpesvirus 1 infection in haemoplasma-infected cats supports co-transmission. Vet. J. 2016, 214, 117–121.
  89. Novacco, M.; Ranjbar Kohan, N.; Stirn, M.; Meli, M.L.; Díaz-Sánchez, A.; Boretti, F.S.; Hofmann-Lehmann, R. Prevalence, Geographic Distribution, Risk Factors and Co-Infections of Feline Gammaherpesvirus Infections in Domestic Cats in Switzerland. Viruses 2019, 11, 721.
  90. Powers, J.A.; Chiu, E.S.; Kraberger, S.J.; Roelke-Parker, M.; Lowery, I.; Erbeck, K.; Troyer, R.; Carver, S.; VandeWoude, S. Feline leukemia virus (FeLV) disease outcomes in a domestic cat breeding colony: Relationship to endogenous FeLV and other chronic viral infections. J. Virol. 2018, 92, e00649-18.
  91. Rose, E.C.; Tse, T.Y.; Oates, A.W.; Jackson, K.; Pfeiffer, S.; Donahoe, S.L.; Setyo, L.; Barrs, V.R.; Beatty, J.A.; Pesavento, P.A. Oropharyngeal shedding of Gammaherpesvirus DNA by Cats, and Natural Infection of Salivary Epithelium. Viruses 2022, 14, 566.
  92. Parisi, F.; Freer, G.; Mazzanti, C.M.; Pistello, M.; Poli, A. Mouse Mammary Tumor Virus (MMTV) and MMTV-like Viruses: An In-depth Look at a Controversial Issue. Viruses 2022, 14, 977.
  93. Hsu, W.-L.; Lin, H.-Y.; Chiou, S.-S.; Chang, C.-C.; Wang, S.-P.; Lin, K.-H.; Chulakasian, S.; Wong, M.-L.; Chang, S.-C. Mouse mammary tumor virus-like nucleotide sequences in canine and feline mammary tumors. J. Clin. Microbiol. 2010, 48, 4352–4362.
  94. Callahan, R.; Smith, G.H. MMTV-induced mammary tumorigenesis: Gene discovery, progression to malignancy and cellular pathways. Oncogene 2000, 19, 992–1001.
  95. Parisi, F.; Muscatello, L.V.; Civita, P.; Lessi, F.; Menicagli, M.; Millanta, F.; Brunetti, B.; Benazzi, C.; Sarli, G.; Freer, G.; et al. Pathological Features and Molecular Phenotype of MMTV Like-Positive Feline Mammary Carcinomas. Animals 2021, 11, 2821.
  96. Amber, K.; McLeod, M.P.; Nouri, K. The Merkel cell polyomavirus and its involvement in Merkel cell carcinoma. Dermatol. Surg. 2013, 39, 232–238.
  97. Munday, J.S.; Thomson, N.A. Papillomaviruses in Domestic Cats. Viruses 2021, 13, 1664.
  98. Munday, J.S. Papillomaviruses in felids. Vet. J. 2014, 199, 340–347.
  99. Munday, J.S.; Sharp, C.R.; Beatty, J. Novel Virus: Update on the significance of papillomavirus infections in cats. J. Feline Med. Surg. 2019, 21, 409–418.
  100. Munday, J.S.; Kiupel, M. Papillomavirus-Associated Cutaneous Neoplasia in Mammals. Vet. Pathol. 2010, 47, 254–264.
  101. Ito, S.; Chambers, J.K.; Mori, C.; Sumi, A.; Omachi, T.; Nakayama, H.; Uchida, K. Comparitive In Vitro and In Vivo studies on Feline, Canine, and Human Merkel Cell Carcinoma. Vet. Pathol. 2021, 58, 276–287.
  102. Ito, S.; Chambers, J.K.; Sumi, A.; Yamashita-Kawanishi, N.; Omachi, T.; Haga, T.; Nakayama, H.; Uchida, K. Involvement of Felis catus papillomavirus type 2 in the tumorigenesis of feline Merkel cell carcinoma. Vet. Pathol. 2022, 59, 63–74.
  103. Egberink, H.; Thiry, E.; Mostl, K.; Addie, D.; Belak, S.; Boucraut-Baralon, C.; Frymus, T.; Gruffydd-Jones, T.; Hosie, M.; Hartmann, K.; et al. Feline Viral Papillomatosis: ABCD guidelines on prevention and management. J. Feline Med. Surg. 2013, 15, 560–562.
  104. Munday, J.S.; French, A.F.; Peters-Kennedy, J.; Orbell, G.M.B.; Gwynne, K. Increased p16CDKN2A Protein Within Feline Cutaneous Viral Plaques, Bowenoid In Situ Carcinomas, and a Subset of Invasive Squamous Cell Carcinoma. Vet. Pathol. 2011, 48, 460–465.
  105. Vascellari, M.; Mazzei, M.; Zanardello, C.; Melchiotti, E.; Albanese, F.; Forzan, M.; Abramo, F. Felis catus Papillomavirus Types 1, 2, 3, 4, and 5 in Feline Bowenoid in Situ Carcinoma: An In Situ Hybridization Study. Vet. Pathol. 2019, 56, 818–825.
  106. Demos, L.E.; Munday, J.S.; Lange, C.E.; Bennett, M.D. Use of fluorescence in situ hybridization to detect Felis catus papullomavirus in feline Bowenoid in situ carcinoma. J. Feline Med. Surg. 2019, 21, 575–580.
  107. Wilhelm, S.; Degorce-Rubiales, F.; Godson, D.; Favrot, C. Clinical, histological and immunohistochemical study of feline viral plaques and bowenoid in situ carcinomas. Vet. Dermatol. 2006, 17, 424–431.
  108. Kok, M.K.; Yamashita-Kawanishi, N.; Chambers, J.K.; Haritani, M.; Ushigusa, T.; Haga, T.; Nakayama, H.; Uchida, K. Pathologica characterization of Felis catus papillomavirus type 5 (FcaPV-5)-associated viral plaques and Bowenoid in situ carcinoma in a Domestic Shorthair cat. J. Vet. Med. Sci. 2019, 81, 660–666.
  109. Lange, C.E.; Tobler, K.; Markau, T.; Alhaidari, Z.; Bornand, V.; Stöcklif, R.; Trüsselg, M.; Ackermannb, M.; Favrota, C. Sequence and classification of FdPV2, a papillomavirus isolated from feline Bowenoid in situ carcinomas. Vet. Microbiol. 2009, 137, 60–65.
  110. Munday, J.S.; Benfell, M.W.; French, A.F.; Orbell, G.M.B.; Thomson, N.A. Bowenoid in situ carcinomas in two Devon Rex cats: Evidence of unusually aggressive neoplasm behaviour in this breed and detection of papillomaviral gene expression in primary and metastatic lesions. Vet. Dermatol. 2016, 27, 215-e55.
  111. Munday, J.S.; Fairley, R.; Atkinson, K. The detection of Felis catus papillomavirus 3 DNA in a feline bowenoid in situ carcinoma with novel histologic features and benign clinical behavior. J. Vet. Diagn. Investig. 2016, 28, 612–615.
  112. Favrot, C.; Welle, M.; Heimann, M.; Godson, D.L.; Gusdetti, F. Clinical, histologic, and immunohistochemical analyses of feline squamous cell carcinoma in situ. Vet. Pathol. 2009, 46, 25–33.
  113. Munday, J.S.; Kiupel, M.; French, A.F.; Howe, L. Amplification of papillomaviral DNA sequences from a high proportion of feline cutaneous in situ and invasive squamous cell carcinomas using a nested polymerase chain reaction. Vet. Dermatol. 2008, 19, 259–263.
  114. Thomson, N.A.; Munday, J.S.; Dittmer, K.E. Frequent detection of transcriptionally active Felis catus papillomavirus 2 in feline cutaneous squamous cell carcinomas. J. Gen. Virol. 2016, 97, 1189–1197.
  115. Altamura, G.; Power, K.; Martano, M.; degli Uberti, B.; Galiero, G.; De Luca, G.; Maiolino, P.; Borzacchiello, G. Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP/p53 binding and enhances p53 proteasomal degradation. Nature 2018, 8, 17529.
  116. Altamura, G.; Cardeti, G.; Cersini, A.; Eleni, C.; Cocumelli, C.; del Pino, L.E.B.; Razzuoli, E.; Martano, M.; Maiolino, P.; Borzacchiello, G. Detection of Felis catus papillomavirus type-2 DNA and viral gene expression suggest active infection in feline oral squamous cell carcinoma. Vet. Comp. Oncol. 2020, 18, 494–501.
  117. Altamura, G.; Corteggio, A.; Pacini, L.; Conte, A.; Pierantoni, G.M.; Tommasino, M.; Accardi, R.; Borzacchiello, G. Transforming properties of Felis catus papillomavirus type 2 E6 and E7 putative oncogenes in vitro and their transcriptional activity in feline squamous cell carcinoma in vivo. Virology 2016, 496, 1–8.
  118. Munday, J.S.; Gibson, I.; French, A.F. Papillomaviral DNA and increased p16CDKN2A protein are frequently present within feline cutaneous squamous cell carcinomas in ultraviolet-protected skin. Vet. Dermatol. 2011, 22, 360–366.
  119. Munday, J.S.; French, A.F.; Thomson, N. Detection of DNA sequences from a novel papillomavirus in a feline basal cell carcinoma. Vet. Dermatol. 2017, 28, 236-e60.
  120. Munday, J.S.; Thomson, N.A.; Henderson, G.; Fairley, R.; Orbell, G.M. Identification of Felis catus papillomavirus 3 in skin neoplasms from four cats. J. Vet. Diagn. Investig. 2018, 30, 324–328.
  121. Teifke, J.P.; Kidney, B.A.; Löhr, C.V.; Yager, J.A. Detection of papillomavirus-DNA in mesenchymal tumour cells and not in the hyperplastic epithelium of feline sarcoids. Vet. Dermatol. 2003, 14, 47–56.
  122. Munday, J.S.; Gedye, K.; Daudt, C.; Da Silva, F.C. The development of novel primer sets to specifically amplify each of the five different Deltapapillomaviruses that cause neoplasia after cross-species infection. Vet. Sci. 2021, 8, 208.
  123. Munday, J.S.; Thomson, N.; Dunowska, M.; Knight, C.G.; Laurie, R.E.; Hills, S. Genomic characterisation of the feline sarcoid-assoicated papillomavirus and proposed classification as Bos taurus papillomavirus type 14. Vet. Microbiol. 2015, 177, 289–295.
  124. Munday, J.S.; Knight, C.G.; Howe, L. The same papillomavirus is present in feline sarcoids from North America and New Zealand but not in any non-sarcoid feline samples. J. Vet. Diagn. Investig. 2010, 22, 97–100.
  125. Sundberg, J.P.; Van Ranst, M.; Montali, R.; Homer, B.L.; Miller, W.H.; Rowland, P.H.; Scott, D.W.; England, J.J.; Dunstan, R.W.; Mikaelian, I.; et al. Feline papillomas and papillomaviruses. Vet. Pathol. 2000, 37, 1–10.
  126. Munday, J.S.; Fairley, R.A.; MIlls, H.; Kiupel, M.; Vaatstra, B.L. Oral papillomas associated with Felis catus papillomavirus type 1 in 2 domestic cats. Vet. Pathol. 2015, 52, 1187–1190.
  127. Munday, J.S.; Howe, L.; French, A.; Squires, R.A.; Sugiarto, H. Detection of papillomaviral DNA sequences in a feline oral squamous cell carcinoma. Res. Vet. Sci. 2009, 86, 359–361.
  128. O’Neill, S.H.; Newkirk, K.M.; Anis, E.A.; Brahmbhatt, R.; Frank, L.A.; Kania, S.A. Detection of human papillomavirus DNA in feline premalignant and invasive squamous cell carcinoma. Vet. Dermatol. 2011, 22, 68–74.
  129. Yamashita-Kawanishi, N.; Sawanobori, R.; Matsumiya, K.; Uema, A.; Chambers, J.K.; Uchida, K.; Shimakura, H.; Tsuzuki, M.; Chang, C.Y.; Chang, H.W.; et al. Detection of felis catus papillomavirus type 3 and 4 DNA from squamous cell carcinoma cases of cats in Japan. J. Vet. Med. Sci. 2018, 80, 1236–1240.
  130. Munday, J.S.; Knight, C.G.; French, A.F. Evaluation of feline oral squamous cell carcinomas for p16CDKN2A protein immunoreactivity and the presence of papillomaviral DNA. Res. Vet. Sci. 2011, 90, 280–283.
  131. Munday, J.S.; French, A.F. Felis catus papillomavirus types 1 and 4 are rarely present in neoplastic and inflammatory oral lesions of cats. Res. Vet. Sci. 2015, 100, 200–222.
  132. Rizzo, G.E.M.; Cabibbo, G.; Craxi, A. Hepatitis B Virus-Associated Hepatocellular Carcinoma. Viruses 2022, 14, 986.
  133. Aghazadeh, M.; Shi, M.; Barrs, V.R.; McLuckie, A.J.; Lindsay, S.A.; Jameson, B.; Hampson, B.; Holmes, E.C.; Beatty, J.A. A novel hepadnavirus identified in an immunocompromised domestic cat in Australia. Viruses 2018, 10, 269.
  134. Lanave, G.; Capozza, P.; Diakoudi, G.; Catella, C.; Catucci, L.; Ghergo, P.; Stasi, F.; Barrs, V.; Beatty, J.; DeCaro, N.; et al. Identification of hepadnavirus in the sera of cats. Sci. Rep. 2019, 9, 10668.
  135. Pesavento, P.A.; Jackson, K.; Scase, T.; Tse, T.; Hampson, B.; Munday, J.S.; Barrs, V.R.; Beatty, J. A novel Hepadnavirus is associated with chrinic heaptitis and heparocellular carcinoma in cats. Viruses 2019, 11, 969.
  136. Aghazadeh, M.; Shi, M.; Pesavento, P.A.; Durham, A.C.; Polley, T.; Donahoe, S.L.; Troyer, R.M.; Barrs, V.R.; Holmes, E.C.; Beatty, J.A. Transcriptome Analysis and In Situ Hybridization for FcaGHV1 in Feline Lymphoma. Viruses 2018, 10, 464.
  137. Strauss-Ayali, D.; Scanziani, E.; Deng, D.; Simpson, K.W. Helicobacter spp. infection in cats: Evaluation of the humoural immune response and prevalence of gastric Helicobacter spp. Vet. Microbiol. 2001, 79, 253–265.
  138. Bridgeford, E.C.; Marini, R.P.; Feng, Y.; Parry, N.M.A.; Rickman, B.; Fox, J.G. Gastric Helicobacter species as a cause of feline gastric lymphoma: A viable hypothesis. Vet. Immunol. Immunopathol. 2008, 123, 106–113.
  139. Ferguson, A.R. Associated bilharziosis and primary malignant disease of the urinary bladder, with observations on a series of forty cases. J. Pathol. 1911, 16, 76–94.
  140. van Tong, H.; Brindley, P.J.; Meyer, C.G.; Velavan, T.P. Parasite Infection, Carcinogenesis and Human Malignancy. EBioMedicine 2017, 15, 12–23.
  141. Santos, J.A.; Lopes, M.A.F.; Schott, A.C.; Santos, A.E.S.; Porfirio, L.C.; Passos, L. Colangiocarcinomas em gatos com parasitismo de ductos biliares por Platynosomum fastosum. Pesqui. Vet. Bras. 1981, 1, 31–36.
  142. Andrade, R.L.F.S.; Dantas, A.F.M.; Galiza, G.J.N.; Carvalho, F.K.L. Platynosomum fastosum-induced cholangiocarcinomas in cats. Vet. Parasitol. 2012, 190, 277–280.
  143. Tiwananthagorn, S.; Srivorakul, S.; Khochakul, V. Biliary cystadenoma associated with Opisthorchis viverrini infection in a domestic cat (Felis catus). Vet. Parasitol. 2018, 258, 138–141.
  144. Gouveia, M.J.; Pakharukova, M.Y.; Laha, T.; Sripa, B.; Maksimova, G.A.; Rinaldi, G.; Brindley, P.J.; Mordvinov, V.A.; Amaro, T.; Santos, L.L.; et al. Infection with Opisthorchis felineus induces intraepithelial neoplasia of the biliary tract in a rodent model. Carcinogenesis 2017, 38, 929–937.
  145. Kaewpitoon, N.; Kaewpitoon, S.J.; Pengsaa, P.; Sripa, B. Opisthorchis viverrini: The carcinogenic human liver fluke. World J. Gastroenterol. 2008, 14, 666–674.
  146. Pakharukova, M.Y.; Zaparina, O.G.; Kapushchak, Y.K.; Baginskaya, N.V.; Mordvinov, V.A. Opisthorchis felineus infection provokes time-dependent accumulation of oxidative hepatobiliary lesions in the injured hamster liver. PLoS ONE 2019, 14, e0216757.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback